About Connext
Connext is a company based in Yeongcheon-si (South Korea) founded in 2017. It operates as a HealthTech and Licensing Model. Connext has raised $9.93 million across 1 funding round from investors including Pharmaresearch. Connext offers products and services including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase). Connext operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others.
- Headquarter Yeongcheon-si, South Korea
- SectorsHealthcare
- Email••••••••
- Website connext.co.kr
- Social Facebook
- Legal Name Connext Co., Ltd.
- Total Equity Funding$9.93M (USD)
in 1 rounds
- Latest Funding Round$9.93M (USD), Series C
Mar 2026
- Investors
Products & Services of Connext
Connext offers a comprehensive portfolio of products and services, including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase).
Developed to prevent side effects in cancer treatments.
Designed to treat Dupuytren's contracture and related conditions.
Funding Insights of Connext
Connext has successfully raised a total of $9.93M through 1 strategic funding round. The most recent funding activity was a Series C round of $9.93 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.93M
- Total Rounds 1
- Last Round Series C — $9.93M
- First Round $9.93M
(Mar 2026)
- Investors Count 1
All 1 funding rounds of Connext with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $9.93M | Series C | – | – |
1 investors in total: 1 institutional.
Investors in Connext
Connext has secured backing from 1 investor. Prominent investors backing the company include Pharmaresearch.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | pharmaresearch.com | - |
Investor details for Connext
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Connext
1 people are tracked at Connext (1 in leadership).
| Name | Role | Group |
|---|---|---|
Woo-Jong Lee | CEO & Owner | Leadership |
Complete people profiles for Connext
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Connext
2 dated milestones of Connext across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Connext is founded.
- Funding First funding round of $9.9M.
Competitors of Connext
Connext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Connext
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Connext
The website of Connext (connext.co.kr) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 5.6% vs previous month
Similar companies to Connext
10 companies that operate in the same segment as Connext (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | – | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Connext
Connext was founded in 2017 and raised its 1st funding round 9 years after it was founded.
Connext is headquartered in Yeongcheon-si, South Korea. It is registered at Yeongcheon-si, North Gyeongsang Province, South Korea.
Woo-Jong Lee is the current CEO of Connext.
Connext is a funded company, having raised a total of $9.93M across 1 funding round to date. The company's 1st funding round was a Series C of $9.93M, raised on Mar 2026.
Connext, a clinical-stage bioventure, is focused on the development of biopharmaceuticals aimed at enhancing quality of life. Innovative drugs are being developed to prevent side effects from cancer and radiation therapies using recombinant TLR5 agonist technology. Additionally, the worlds first recombinant collagenase treatment is under development for conditions like Dupuytrens contracture. The company is expanding its pipeline in immuno-oncology and regenerative medicine sectors. Efforts are made to introduce, develop, and commercialize cutting-edge biotechnologies for global health impact.
Connext's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Connext offers CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase).
Connext has 1 investor. Key investors include Pharmaresearch.
Connext operates through Connext Co., Ltd..